Janux Therapeutics, Inc. Accrued Liabilities, Current
Janux Therapeutics, Inc. (JANX) had Accrued Liabilities, Current of $19.51 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $19.51M.
- 2026-03-31: Accrued Liabilities, Current $15.48M.
- 2025-12-31: Accrued Liabilities, Current $17.63M.
- 2025-09-30: Accrued Liabilities, Current $22.16M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $19.51M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $15.48M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $17.63M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $22.16M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $16.03M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $13.34M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $11.68M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $13.02M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $8.57M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $5.81M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $7.39M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $6.83M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $9.22M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $7.74M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $8.18M 10-K · filed 2024-03-08 | $8.01M 10-K · filed 2023-03-10 |
| 2022-09-30 | $7.24M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $4.04M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $5.07M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $3.78M 10-K · filed 2023-03-10 | |
| 2021-09-30 | $2.03M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.29M 10-Q · filed 2021-08-10 | |
| 2020-12-31 | $751.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |